Measuring current and future cost of skin cancer in England

Vallejo-Torres, Laura; Morris, Stephen; Kinge, Jonas Minet; Poirier, Véronique; Verne, Julia

doi:10.1093/pubmed/fdt032

Cited by 86 publications

(98 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 The total cost of skin cancer to the NHS is projected to be over £180 million in 2020, constituting a substantial burden to the British health services. 3 There are currently no national guidelines in Scotland regarding primary care management of BCC and SCC, although the Scottish Intercollegiate Guidelines Network (SIGN) has recently proposed a guideline on management of SCC, which is due to be published in 2014. SIGN number 72 on melanoma states: 'GPs should refer urgently all patients in whom melanoma is a strong possibility rather than carry out a biopsy in primary care.'…”

Section: Introductionmentioning

confidence: 99%

Skin cancer excision performance in Scottish primary and secondary care: a retrospective analysis

et al. 2014

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Skin cancer excision performance in Scottish primary and secondary care: a retrospective analysis

et al. 2014

View full text Add to dashboard Cite

“…An independent company confirmed this amount with an estimation of £106-112 million [42]. In 2013 there were 40 cases of malignant melanoma diagnosed on a daily basis [3], each costing between £2507-2560.…”

Section: Primary Prevention Benefits -Cost-effectivementioning

confidence: 95%

“…In 2008 the United Kingdom Health department determined that £105.2 million was spent on skin cancer management [42].…”

Section: Primary Prevention Benefits -Cost-effectivementioning

confidence: 99%

See 1 more Smart Citation

Skin cancer in the youth population of the United Kingdom

Robertson

Fitzgerald

2017

Journal of Cancer Policy

View full text Add to dashboard Cite

a b s t r a c tSkin cancer is disproportionately high in the youth population of the United Kingdom, as compared with other cancers, yet it is a topic which so far has received little recognition, subsequently relevant literature is relatively scarce. In the United Kingdom, malignant melanoma is now one of the commonest cancers in those aged 15-34 years. Furthermore, malignant melanoma the 7th most common cancer in men, and 5th most common cancer in women in the United Kingdom in 2013 accounting for 4% of all cancer cases in the United Kingdom. Moreover, skin cancer is currently the fastest growing cancer in the world with a five-fold increase in frequency since the 1970 s resulting in disfigurement and death.This essay explores this skin cancer age-related anomaly through the lens of public health. A scoping review combined with a thematic analysis of literature, identified risk factors including demographic and environmental risk factors within the youth population. Research suggests that 86% of cases could be prevented alleviating the current financial burden of over £100 million spent on managing skin cancer.

show abstract

“…Cerrahi eksizyon BHK tedavisinde uzak ara en sık uygulanan yöntemdir 18,19 . Standart eksizyon 5 yıllık rekürrens oranlarının %2-10 arasında değiştiği bütün primer BHK olgularda etkili tedavi seçeneğidir [20][21][22] .…”

Section: Bhk Tedavi Seçenekleri Ve Güncel Yaklaşımlarunclassified

Current Advances in the Treatment of Basal Cell Carcinoma

Çalış¹,

Uzun²

2016

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETBazal hücreli karsinom, derinin en sık görülen malign tümörü olup insidansı giderek artmaktadır. Predispozan faktörler arasında en önemlisi güneş ışınlarına maruz kalmaktır. Bununla birlikte genetik hastalıklar, organ nakilleri ve immünsupresyon da bazal hücreli karsinom gelişimini tetiklemektedir. Oldukça nadir metastaz yapmasına rağmen lokal agresif seyreder. Ana tedavi şekli cerrahi olup cerrahiye aday olmayan hastalarda radyoterapi, kriyoterapi, kemoterapi ve hedgehog yolak inhibitörleri kullanılabilir. Bu derlemede bazal hücreli karsinomun tedavisi konusunda güncel gelişmeler tartışılmıştır.Anahtar Kelimeler: bazal hücreli karsinom, cerrahi, vismodegib ABSTRACT Basal cell carcinoma is the most commonly seen malignant tumor of the skin and its incidence is gradually increasing. Sun exposure is the single most important predisposing factor. In addition, genetic disorders, organ transplantations and immunesupression may trigger the development of basal cell carcinoma. Although it metastasizes rarely, its clinical course is local aggressive. The main treatment modality is surgery. In patients who are not candidates for surgery; radiotherapy, cryotherapy, chemotherapy and hedgehog pathway modulators can be used. In this review, current advances in the treatment of basal cell carcinoma is discussed.

show abstract

Measuring current and future cost of skin cancer in England

Abstract: Effective prevention of skin cancer might not only reduce a significant burden of disease but it could also save considerable resources to the NHS.

Cited by 86 publications

References 16 publications

Skin cancer excision performance in Scottish primary and secondary care: a retrospective analysis

Skin cancer excision performance in Scottish primary and secondary care: a retrospective analysis

Skin cancer in the youth population of the United Kingdom

Current Advances in the Treatment of Basal Cell Carcinoma

Contact Info

Product

Resources

About